{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:31Z","timestamp":1789011331762,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13104-016-2189-x","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T13:28:51Z","timestamp":1470230931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Charlotte R.","family":"Lemech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McCaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"issue":"3","key":"2189_CR1","first-page":"562","volume":"122","author":"L Monda","year":"1986","unstructured":"Monda L, Warnke R, Rosai J. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol. 1986;122(3):562\u201372.","journal-title":"Am J Pathol"},{"issue":"1","key":"2189_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","volume":"41","author":"SA Pileri","year":"2002","unstructured":"Pileri SA, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41(1):1\u201329.","journal-title":"Histopathology"},{"key":"2189_CR3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-065X.1990.tb00573.x","volume":"117","author":"JG Tew","year":"1990","unstructured":"Tew JG, et al. Follicular dendritic cells as accessory cells. Immunol Rev. 1990;117:185\u2013211.","journal-title":"Immunol Rev"},{"issue":"1","key":"2189_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1309\/AJCP7U8YISBUAVNW","volume":"133","author":"GJ Duan","year":"2010","unstructured":"Duan GJ, et al. Extranodal follicular dendritic cell sarcoma of the pharyngeal region: a potential diagnostic pitfall, with literature review. Am J Clin Pathol. 2010;133(1):49\u201358.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2189_CR5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<294::AID-CNCR13>3.3.CO;2-U","volume":"79","author":"JK Chan","year":"1997","unstructured":"Chan JK, et al. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized. Cancer. 1997;79(2):294\u2013313.","journal-title":"Cancer"},{"issue":"8","key":"2189_CR6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ajh.20852","volume":"82","author":"AO Soriano","year":"2007","unstructured":"Soriano AO, et al. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007;82(8):725\u20138.","journal-title":"Am J Hematol"},{"issue":"20","key":"2189_CR7","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.3748\/wjg.v16.i20.2504","volume":"16","author":"L Li","year":"2010","unstructured":"Li L, et al. Clinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcoma. World J Gastroenterol. 2010;16(20):2504\u201319.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2189_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/COC.0b013e31824be22b","volume":"36","author":"SM Perkins","year":"2013","unstructured":"Perkins SM, Shinohara ET. Interdigitating and follicular dendritic cell sarcomas: a SEER analysis. Am J Clin Oncol. 2013;36(4):395\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2189_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<161::AID-AJH10>3.0.CO;2-C","volume":"59","author":"R Fonseca","year":"1998","unstructured":"Fonseca R, et al. Follicular dendritic cell sarcoma and interdigitating reticulum cell sarcoma: a review. Am J Hematol. 1998;59(2):161\u20137.","journal-title":"Am J Hematol"},{"issue":"17","key":"2189_CR10","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1200\/JCO.2013.49.3213","volume":"33","author":"JS Starr","year":"2015","unstructured":"Starr JS, et al. Follicular dendritic cell sarcoma presenting as a thyroid mass. J Clin Oncol. 2015;33(17):e74\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2189_CR11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1309\/7P8U659JBJCV6EEU","volume":"128","author":"H Yu","year":"2007","unstructured":"Yu H, et al. Podoplanin (D2\u201340) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol. 2007;128(5):776\u201382.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2189_CR12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.2420","volume":"216","author":"W Vermi","year":"2008","unstructured":"Vermi W, et al. Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol. 2008;216(3):356\u201364.","journal-title":"J Pathol"},{"issue":"2","key":"2189_CR13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/his.12416","volume":"65","author":"H Go","year":"2014","unstructured":"Go H, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261\u201372.","journal-title":"Histopathology"},{"issue":"1","key":"2189_CR14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/modpathol.2015.130","volume":"29","author":"GK Griffin","year":"2016","unstructured":"Griffin GK, et al. Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-kappaB regulatory genes. Mod Pathol. 2016;29(1):67\u201374.","journal-title":"Mod Pathol"},{"issue":"8","key":"2189_CR15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/00000478-199608000-00003","volume":"20","author":"B Perez-Ordonez","year":"1996","unstructured":"Perez-Ordonez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor: report of 13 additional cases of a distinctive entity. Am J Surg Pathol. 1996;20(8):944\u201355.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2189_CR16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2012","unstructured":"Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12(1):68\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2189_CR17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.bjc.6603535","volume":"96","author":"E Levy-Lahad","year":"2007","unstructured":"Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2007;96(1):11\u20135.","journal-title":"Br J Cancer"},{"issue":"2","key":"2189_CR18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"issue":"9","key":"2189_CR19","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","volume":"13","author":"CK Donawho","year":"2007","unstructured":"Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728\u201337.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2189_CR20","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588\u201399.","journal-title":"Cancer Res"},{"issue":"6","key":"2189_CR21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4161\/cc.24034","volume":"12","author":"J Michels","year":"2013","unstructured":"Michels J, et al. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle. 2013;12(6):877\u201383.","journal-title":"Cell Cycle"},{"issue":"3","key":"2189_CR22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ygyno.2015.03.042","volume":"137","author":"RL Coleman","year":"2015","unstructured":"Coleman RL, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation\u2014an NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2015;137(3):386\u201391.","journal-title":"Gynecol Oncol"},{"issue":"Suppl 15","key":"2189_CR23","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1200\/jco.2014.32.15_suppl.2570","volume":"32","author":"S Puhalla","year":"2014","unstructured":"Puhalla S, et al. Final results of a phase 1 study of single-agent veliparib (V) in patients (pis) with either BRCA1\/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt). J Clin Oncol. 2014;32 Suppl 15:2570.","journal-title":"J Clin Oncol"},{"issue":"Suppl 24","key":"2189_CR24","doi-asserted-by":"crossref","first-page":"Abstract: S5\u201302","DOI":"10.1158\/0008-5472.SABCS13-S5-02","volume":"73","author":"HS Rugo","year":"2013","unstructured":"Rugo HS, et al. Veliparib\/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL. Cancer Res. 2013;73 Suppl 24:Abstract: S5\u201302.","journal-title":"Cancer Res"},{"issue":"Suppl 15","key":"2189_CR25","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/jco.2014.32.15_suppl.1021","volume":"32","author":"G Somlo","year":"2014","unstructured":"Somlo G, et al. Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96. J Clin Oncol. 2014;32 Suppl 15:1021.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2189_CR26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","volume":"122","author":"MP Mehta","year":"2015","unstructured":"Mehta MP, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol. 2015;122(2):409\u201317.","journal-title":"J Neurooncol"},{"issue":"10","key":"2189_CR27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen KA, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355(10):983\u201391.","journal-title":"N Engl J Med"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-016-2189-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T03:44:29Z","timestamp":1568259869000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-016-2189-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1186\/s13104-016-2189-x","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,3]]},"article-number":"386"}}